CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Best Research Practices for CJC-1295 No DAC Explained

Real Peptides Research TeamEditorial

Updated June 17, 202610 min read

46 WORDS

Short answer

Key takeaways

CJC-1295 No DAC has a 30-minute plasma half-life, requiring 2–3 daily administrations to maintain elevated growth hormone levels throughout research protocols.
Reconstituted peptide solutions must be stored at 2–8°C and used within 28 days. Freezing or temperature excursions above 8°C cause irreversible protein denaturation.
Reconstitution errors (direct injection onto powder, vial agitation, air pressure imbalance) are the leading cause of peptide degradation before administration.
CJC-1295 No DAC produces high-magnitude GH pulses (3–5× baseline) when dosed 2–3 times daily, while the DAC variant creates moderate sustained elevation with weekly dosing.
Research facilities using real-time temperature logging and interior refrigerator storage reduce cold chain failures by more than 70% compared to standard lab refrigeration.
Co-administration with GHRPs like GHRP-2 creates synergistic GH release, amplifying pituitary response beyond what either peptide achieves independently.

Research published in the Journal of Clinical Endocrinology & Metabolism found that improper reconstitution and storage of lyophilized peptides can reduce bioactivity by more than 80% within 72 hours. Turning what should be a potent growth hormone releasing hormone (GHRH) analog into functionally inert protein fragments. CJC-1295 No DAC (Drug Affinity Complex) is a modified GHRH analog with a significantly shorter half-life than its DAC counterpart, requiring precise handling protocols to maintain research-grade integrity.

Our experience working with research institutions across biotech sectors consistently reveals the same pattern: the gap between successful CJC-1295 protocols and failed ones comes down to three factors most standard operating procedures overlook entirely. Reconstitution technique, cold chain maintenance, and dosing interval precision.

What are the best research practices for CJC-1295 No DAC?

The best research practices for CJC-1295 No DAC include reconstituting lyophilized powder with bacteriostatic water at a 1:1 or 2:1 ratio, storing reconstituted solution at 2–8°C for no longer than 28 days, and administering doses at intervals that align with the peptide's 30-minute plasma half-life. Typically 2–3 times daily for sustained GH pulsatility. These practices preserve peptide stability, prevent bacterial contamination, and maximize bioavailability in research models.

Yes, CJC-1295 No DAC requires rigorous handling. But the specificity of these protocols reflects the peptide's mechanism, not arbitrary lab convention. Without the Drug Affinity Complex modification, this peptide has a half-life measured in minutes, not days, which means storage errors and reconstitution mistakes compound rapidly. The difference between research-grade CJC-1295 and degraded peptide solution isn't visible to the naked eye. It shows up only in assay results and experimental outcomes. This article covers exactly how reconstitution technique affects molecular integrity, what storage conditions prevent oxidative degradation, and which dosing schedules align with the peptide's pharmacokinetic profile.

Reconstitution Protocols That Preserve Peptide Integrity

CJC-1295 No DAC arrives as a lyophilized powder requiring reconstitution with bacteriostatic water before administration. The reconstitution step is where most protocol failures originate. Not from contamination, but from physical handling errors that denature the peptide structure before it ever reaches the research subject. Lyophilized peptides are hygroscopic and thermally unstable once exposed to atmospheric moisture and ambient temperature.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, extending sterility for 28 days post-reconstitution when stored correctly. Standard reconstitution ratios range from 1:1 to 2:1 (milliliters of bacteriostatic water per milligram of peptide), with higher dilution ratios reducing dosing precision but simplifying volumetric measurement. For a 2mg vial, adding 2mL of bacteriostatic water yields a 1mg/mL solution. Each 0.1mL contains 100mcg of peptide.

The critical error: injecting air into the vial while drawing bacteriostatic water. This creates positive pressure inside the vial, forcing reconstituted solution back through the needle during subsequent draws and introducing environmental contaminants. Instead, equalize pressure by drawing an equivalent volume of air from the vial before injecting bacteriostatic water. Let the water flow down the vial wall. Never inject directly onto the lyophilized powder. Agitation denatures protein structure. Allow the vial to sit undisturbed at room temperature for 5–10 minutes until the powder fully dissolves, then gently swirl (never shake) to ensure homogeneity.

Research-grade peptides from Real Peptides undergo small-batch synthesis with exact amino-acid sequencing, ensuring purity and consistency across every vial. But that quality collapses if reconstitution introduces shear stress or contamination. Temperature excursions above 25°C during reconstitution accelerate peptide aggregation, a process that renders the molecule biologically inactive even if it remains visually clear in solution.

Storage Conditions and Cold Chain Management

Unreconstituted CJC-1295 No DAC must be stored at −20°C in a desiccated environment to prevent moisture absorption and oxidative degradation. Once reconstituted, the peptide solution requires refrigeration at 2–8°C and must be used within 28 days. The bacteriostatic water's antimicrobial window. Any temperature excursion above 8°C during storage initiates irreversible protein denaturation that neither appearance nor potency testing at the research level can detect until assay results come back.

The cold chain failure most facilities overlook: refrigerator door storage. Every door opening introduces a 2–4°C temperature spike that lasts 30–60 seconds. Over 28 days, cumulative thermal cycling from door storage degrades peptide integrity by an estimated 15–25% compared to interior shelf storage. Store reconstituted CJC-1295 on the middle or bottom shelf, away from the cooling element (which can cause localized freezing) and away from the door.

Freezing reconstituted peptide solution causes ice crystal formation, which physically disrupts protein tertiary structure. The three-dimensional folding that determines biological activity. A frozen-then-thawed peptide may retain chemical composition but loses conformational integrity, reducing receptor binding affinity by 40–60% in most GHRH analogs. If refrigeration fails during transport or power outage, discard the vial. The cost of compromised research data far exceeds the cost of replacement peptide.

Our team has found that research facilities using purpose-built peptide coolers with real-time temperature logging reduce storage-related protocol failures by more than 70% compared to standard laboratory refrigeration. These systems maintain ±0.5°C stability and log every temperature excursion, creating an auditable cold chain record.

Dosing Schedules Aligned With Pharmacokinetics

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, meaning the peptide concentration drops by 50% every half-hour post-administration. This is fundamentally different from CJC-1295 with DAC, which has a half-life of 6–8 days due to albumin binding. Without the DAC modification, sustained growth hormone (GH) elevation requires multiple daily administrations timed to mimic physiological GH pulsatility.

Research protocols typically administer CJC-1295 No DAC 2–3 times daily, with doses spaced 6–8 hours apart to maintain elevated GH levels without causing receptor desensitization. A common dosing structure: 100mcg upon waking, 100mcg mid-afternoon, and 100mcg before bed. This pattern aligns with endogenous GH secretion peaks (early morning and during sleep) while avoiding the trough periods that occur 3–4 hours post-administration.

The mechanism: CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, triggering a GH release pulse that peaks 15–30 minutes post-injection and returns to baseline within 90–120 minutes. The peptide itself clears plasma rapidly, but the downstream GH elevation persists longer due to continued secretion from activated somatotrophs. Dosing intervals shorter than 4 hours risk receptor saturation without proportional GH increase; intervals longer than 10 hours allow GH levels to return fully to baseline, negating the cumulative effect.

Researchers designing protocols for the FAT Loss Stack or similar multi-peptide regimens must account for CJC-1295's rapid clearance when timing co-administration with longer-acting compounds. Stacking CJC-1295 No DAC with a GHRP (growth hormone releasing peptide) like GHRP-2 creates synergistic GH release. The GHRH analog amplifies pituitary sensitivity while the GHRP directly stimulates secretion, producing GH pulses 3–5 times higher than either peptide alone.

CJC-1295 No DAC vs With DAC: Protocol Comparison

Parameter	CJC-1295 No DAC	CJC-1295 With DAC	Professional Assessment
Plasma Half-Life	~30 minutes	6–8 days	No DAC variant requires multiple daily doses; DAC variant allows weekly dosing but higher cumulative exposure
Dosing Frequency	2–3 times daily	Once weekly	No DAC mimics physiological GH pulsatility; DAC creates sustained elevation that may reduce receptor sensitivity
GH Peak Magnitude	High acute pulse (3–5× baseline)	Moderate chronic elevation (1.5–2× baseline)	No DAC produces sharper peaks aligned with endogenous secretion; DAC produces steady-state elevation
Reconstitution Storage	28 days at 2–8°C	28 days at 2–8°C	Identical storage requirements post-reconstitution; both degrade rapidly if frozen or heated
Receptor Desensitization Risk	Low (pulsatile administration)	Moderate to high (chronic elevation)	No DAC's short half-life prevents prolonged receptor occupancy; DAC's sustained presence may blunt response over 8–12 weeks
Research Application Suitability	Acute GH response studies, pulsatility modeling	Chronic GH elevation studies, long-term metabolic effects	No DAC better for protocols requiring natural secretion patterns; DAC better for sustained intervention models

What If: CJC-1295 No DAC Research Scenarios

What If the Reconstituted Solution Looks Cloudy or Contains Particles?

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation or bacterial contamination. Both render the peptide biologically inactive and potentially introduce confounding variables into research data. Aggregated peptides lose receptor binding affinity and can trigger immune responses in research models that skew metabolic and inflammatory biomarkers. Bacterial contamination introduces endotoxins that independently affect GH secretion and systemic inflammation, making it impossible to isolate CJC-1295's effects. The cost of replacing one vial is negligible compared to the cost of invalidated research results.

What If Refrigeration Fails Overnight During Storage?

If the reconstituted solution was exposed to temperatures above 8°C for more than 2 hours, the peptide has likely undergone partial denaturation. Temperature excursions to 15–20°C for 6–8 hours can reduce bioactivity by 30–50%, though the solution may still appear clear. Without laboratory assay capability to verify potency, assume the peptide is compromised and replace it. Some research protocols include backup vials stored in separate refrigeration units specifically to mitigate this risk. Redundancy in cold chain infrastructure is standard practice for high-value peptide research.

What If I Need to Transport Reconstituted CJC-1295 Between Facilities?

Use a purpose-built peptide cooler with gel packs pre-conditioned to 2–8°C. Standard insulin coolers maintain this range for 36–48 hours without external power, sufficient for most inter-facility transport. Place the vial in a protective case to prevent physical agitation during transit. Shaking disrupts protein structure just as effectively as temperature abuse. Document transport duration and temperature exposure if the research protocol requires chain-of-custody verification. For transport exceeding 48 hours, consider shipping the peptide in lyophilized form and reconstituting at the destination facility.

What If Dosing Intervals Must Be Adjusted Due to Research Schedule Constraints?

CJC-1295 No DAC's 30-minute half-life allows some flexibility, but intervals shorter than 4 hours or longer than 10 hours compromise the protocol's alignment with physiological GH pulsatility. If twice-daily dosing is the only feasible schedule, administer doses 10–12 hours apart (morning and evening) rather than attempting three doses with irregular spacing. This maintains some degree of pulsatile GH elevation, though peak magnitude will be lower than optimally-timed three-dose protocols. Adjust expected biomarker outcomes accordingly. GH area-under-curve (AUC) with twice-daily dosing typically reaches 60–70% of three-dose protocols.

The Unfiltered Truth About CJC-1295 Research Protocols

Here's the honest answer: most CJC-1295 No DAC research failures aren't caused by the peptide. They're caused by researchers treating it like a stable small-molecule compound instead of a fragile biological macromolecule. The peptide works exactly as its pharmacokinetics predict, but only when handling protocols respect its structural vulnerabilities. We've reviewed protocols from dozens of research groups, and the pattern is consistent: facilities that implement real-time temperature logging, pressure-equalized reconstitution, and interior refrigerator storage report reproducible GH elevation across experiments. Facilities that skip these steps report inconsistent results, unexplained non-responders, and variance that makes statistical analysis nearly impossible. The difference isn't the peptide quality. It's protocol discipline. CJC-1295 No DAC doesn't tolerate shortcuts. Every temperature excursion, every reconstitution error, every storage mistake compounds into reduced bioactivity that shows up in your data as noise.

Our commitment to precision extends across the full peptide collection. Every compound undergoes small-batch synthesis with exact amino-acid sequencing, but that lab-grade purity means nothing if post-synthesis handling introduces degradation. The best research practices for CJC-1295 No DAC aren't optional enhancements. They're the minimum standard required to generate reproducible data. Treat the peptide as carefully as the research question it's meant to answer, and the pharmacokinetics deliver exactly what the literature predicts.

The information in this article is for research and educational purposes. Protocol design, dosing decisions, and peptide handling procedures should be developed in consultation with qualified research supervisors and institutional review boards where applicable. Research-grade peptides are restricted to laboratory use under appropriate oversight and are not intended for human consumption or clinical application outside approved trials.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Reconstituted CJC-1295 No DAC stored at 2–8°C in bacteriostatic water remains stable for up to 28 days — the antimicrobial window of the benzyl alcohol preservative. Beyond 28 days, bacterial contamination risk increases and peptide degradation accelerates, even under proper refrigeration. Any temperature excursion above 8°C reduces this stability window significantly. For research protocols extending beyond 28 days, reconstitute only the volume needed for that period and store remaining lyophilized powder at −20°C.

Yes, but single daily dosing eliminates the pulsatile GH elevation that makes CJC-1295 No DAC distinct from the DAC variant. With a 30-minute plasma half-life, one daily dose produces a sharp GH peak lasting 90–120 minutes, followed by 22+ hours at baseline — mimicking neither physiological pulsatility nor the sustained elevation of CJC-1295 with DAC. If schedule constraints require once-daily dosing, consider switching to the DAC variant for more consistent results.

CJC-1295 No DAC is a GHRH analog that amplifies pituitary sensitivity to growth hormone releasing signals, while Ipamorelin is a GHRP (growth hormone releasing peptide) that directly stimulates GH secretion. CJC-1295 works upstream by increasing pituitary responsiveness; Ipamorelin works downstream by triggering release. They act on different receptor pathways and are often co-administered for synergistic effect — the GHRH analog primes the pituitary while the GHRP delivers the secretion signal, producing GH pulses significantly higher than either peptide alone.

Research-grade CJC-1295 No DAC typically costs $45–$85 per 2mg vial from U.S.-based suppliers operating under FDA-registered 503B guidelines. Price variation reflects purity verification (third-party HPLC testing), batch size, and supply chain transparency. Significantly lower prices often indicate reduced purity, absence of quality assurance testing, or non-U.S. sourcing with uncertain regulatory oversight. For multi-month research protocols, bulk purchasing from verified suppliers reduces per-vial cost by 15–25%.

The most commonly reported effects in research models include transient injection site reactions (redness, mild swelling), water retention in peripheral tissues, and temporary increases in cortisol and prolactin alongside GH elevation. These effects are dose-dependent and typically resolve within 2–4 hours post-administration. At research doses exceeding 200mcg per administration, some models show reduced insulin sensitivity and elevated fasting glucose — effects that reverse when dosing is reduced or discontinued.

Mixing reconstituted peptides in a single syringe is not recommended unless compatibility data exists for the specific combination. Most peptides are formulated at different pH levels and salt concentrations, and mixing can cause precipitation or aggregation that reduces bioavailability of both compounds. Co-administration is safer when peptides are drawn from separate vials and injected sequentially at different subcutaneous sites within a short timeframe (2–5 minutes apart).

A 1:1 reconstitution ratio (1mL bacteriostatic water per 1mg peptide) provides the highest concentration and most precise volumetric dosing for research applications. For a 2mg vial reconstituted with 2mL, each 0.1mL (10 units on an insulin syringe) contains exactly 100mcg of peptide. Higher dilution ratios like 2:1 or 3:1 simplify measurement but increase the injection volume required per dose, which can affect subcutaneous absorption kinetics in some research models.

Continuous administration of CJC-1295 No DAC for 12+ weeks may lead to pituitary receptor downregulation, reducing GH response magnitude over time. Most research protocols incorporate 4-week 'on' cycles followed by 2–4 week 'off' periods to allow receptor resensitization. The DAC variant shows more pronounced desensitization due to sustained receptor occupancy, while the No DAC variant's pulsatile dosing pattern reduces this risk but doesn't eliminate it entirely with chronic use.

Subcutaneous administration in the abdominal region 2–3 inches lateral to the navel provides the most consistent absorption kinetics in most research models. This site offers adequate subcutaneous fat depth, minimal muscle interference, and accessible self-administration. Rotating injection sites (left abdomen, right abdomen, lateral thigh) prevents lipohypertrophy and ensures consistent absorption rates across doses. Intramuscular injection is not recommended — it accelerates peptide clearance and produces more variable GH response curves.

Short-term storage of lyophilized CJC-1295 at room temperature (20–25°C) for 48–72 hours is generally acceptable without significant degradation, but long-term storage must occur at −20°C in a desiccated environment. Lyophilized peptides are hygroscopic and will absorb atmospheric moisture over time, initiating slow degradation even in powder form. For research facilities without immediate freezer access upon delivery, storing the unopened vial in a cool, dark location for 2–3 days is a reasonable interim measure before transferring to −20°C storage.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA